•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Why Novartis (NVS) is a Top Value Stock for the Long-Term
Novartis gets approval for first malaria drug for babies and children
Novartis receives approval for first malaria medicine for newborn babies and young infants
Here's Why Novartis (NVS) is a Strong Momentum Stock
Novartis' Cosentyx Misses Primary Goal in Arteritis Phase III Study
Novartis drug Cosentyx fails late-stage trial for artery disease
Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)
Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)
Buy These 5 Low-Leverage Stocks Amid Wall Street's Tricky July Start
Novartis AG (NVS) Hits Fresh High: Is There Still Room to Run?
7 Killer European Stocks To Buy In July
Final Trades: Novartis, Sixth Street, Amazon and the IYF
ProFound Therapeutics Announces Multi-Year Strategic Collaboration with Novartis to Discover and Develop Novel Therapeutics for Cardiovascular Disease
Novartis completes acquisition of Regulus Therapeutics
Novartis: A SWAN Worth Owning
5 Large Drug Stocks That Are Poised to Ride on Sector Recovery
Buy These 5 Low-Leverage Stocks Amid Fresh Iran-Israel War
Novartis AG (NVS) Hit a 52 Week High, Can the Run Continue?
Novartis' Fabhalta Delivers Hemoglobin Gains, Reduces Fatigue In Patients With Rare Blood Disorder
Novartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.